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Cardiac involvement is the leading cause of morbidity and mortality in 
systemic amyloidosis [1]. It occurs in about 50% of patients with systemic light 
chain (AL) amyloidosis and is the dominant clinical feature in patients with 
wild-type transthyretin (ATTR) amyloidosis and many genetic variant forms of 
the latter. Accurate identification and staging of cardiac amyloidosis is the 
crucial first step in management of these patients, involving confirmation of 
amyloid deposits, identification of fibril type, and evaluation of the extent and 
severity of amyloid related organ damage.   
  Cardiovascular magnetic resonance (CMR) has unique advantages in 
identifying cardiac involvement in systemic amyloidosis.  CMR provides 
information about cardiac structure and function but most importantly informs 
us on tissue composition. CMR leverages its intrinsic capacity to characterize 
tissue on the basis of fundamental MR properties (T1 and T2), and these 
intrinsic properties can be accentuated by administration of gadolinium-based 
contrast agents. The latest MR techniques for evaluating late gadolinium 
enhancement (LGE) provide images that are virtually pathognomonic in AL 
and ATTR cardiac amyloidosis [2] with excellent diagnostic accuracy.  
Recently the role of CMR in systemic amyloidosis has evolved beyond just 
diagnostic utility [3-7]. CMR tracks the continuum of amyloid accumulation as 
determined by the transmurality of LGE pattern, progressing from normal 
through subendocardial to transmural LGE. This has greatly elucidated how 
amyloid infiltration leads to dysfunction and has highlighted the potential role 
of LGE as a new prognostic marker that is directly linked to the basic 
pathogenic mechanism underlying amyloid cardiomyopathy [3-7]. 
In this issue of iJACC, Raina et al [8] present a systemic review and meta-
analysis evaluating the prognostic role of LGE imaging in patients with cardiac 
amyloidosis. Studies were included that incorporated patients with systemic 
amyloidosis with known or suspected cardiac involvement undergoing CMR 
with LGE assessment and minimum follow up of 12 months. A systematic 
search of electronic databases identified 7 studies with a total of 425 patients, 
149 events and a mean follow-up of 25 months. Five of these studies were 
prospective, single center studies, with the remainder being retrospective. All-
cause mortality was recorded in all studies. Overall, the prevalence of LGE in 
these studies was 73% (range 28% to 84%). Twenty per cent of patients had 
positive endomyocardial biopsies. The patients with LGE had increased 
mortality compared to those without (pooled odds ratio 4.96; 95% confidence 
interval [CI]: 1.90 to 12.93, p=0.001). The pooled death rate for the LGE-
negative group was significantly lower than for the LGE-positive group (0.07 
[95% CI: 0.03-0.19] vs. 0.25 [95% CI: 0.16-0.39] events per year).  The 
proportion of patients with cardiac biopsy within each study ranged from 3% to 
68%, but the relationship between LGE status and death did not vary 
according to cardiac biopsy proportion across studies.  Although 240 of 425 
patients were from 1 center [6], the analyses were not significantly influenced 
by any 1 individual study. 
The main finding of this meta-analysis is confirmation of the prognostic 
role of LGE in patients with known or suspected cardiac amyloidosis and the 
absence of relationship between study-specific odds ratios relating LGE 
status to death and the proportion of patients with cardiac biopsy.  
The reference standard for the diagnosis and subtyping of amyloid is 
histology, but cardiac biopsy has associated risks and does not provide 
information beyond the presence or absence and type of amyloid in a tiny 
tissue specimen. Amyloid deposits only cause organ dysfunction when the 
amyloid burden exceeds a certain threshold; therefore, a spectrum of disease 
burden exists ranging from small incidental deposits with no clinical 
consequence to very extensive deposits causing severe organ failure, 
typically presenting as restrictive cardiomyopathy with biventricular 
involvement and low cardiac output. Cardiac biopsy may confirm the 
diagnosis, but it cannot determine disease burden because of the patchy 
nature of amyloid. Instead, the clinician requires different tools to characterize 
phenotypes, their stages of evolution, and understand the myocardial 
response and the clinical implication of amyloid deposition. CMR with tissue 
characterization (LGE, but also new imaging techniques such as T1 mapping) 
could have a unique role in cardiac amyloidosis, providing information on the 
impact upon cardiac structure and function in addition to tissue composition.  
The association of amyloid burden represented by the LGE and 
mortality is intriguing, but amyloid infiltration alone does not necessarily 
provide all the answers. A subanalysis was performed to assess the 
association of LGE and events separately in AL and ATTR types.  Patients 
with AL amyloidosis were more likely to die compared to ATTR, although the 
difference did not reach statistical significance. Furthermore, the results in AL 
were consistent with the preliminary analysis of increased mortality in LGE-
positive patients, although the information provided by the studies and the 
number of events was not sufficient to carry out the same analysis in ATTR. 
However when analyzing the differences in LGE between AL and ATTR, the 
transmural LGE pattern was more prevalent in ATTR than AL, yet the 
mortality was different across patients with similar degrees of infiltration: 
patients with AL amyloidosis and transmural LGE were more likely to die than 
ATTR patients with the same LGE extent. This has important implications. 
Cardiac amyloidosis is an exemplar of infiltrative disease: amyloid deposits 
can account for more than one-half of total myocardial mass, but amyloid 
cardiomyopathy is not just about infiltration. The observation that mortality is 
greater in AL than ATTR in the face of an apparently similar degree of amyloid 
infiltration suggests there are additional processes contributing to cardiac 
dysfunction and events in AL type. ATTR fibrils are derived from transthyretin, 
a normal plasma transport protein, whereas AL fibrils are composed of unique 
monoclonal immunoglobulin AL proteins that differ in each patient. Although 
all amyloid fibrils have essentially similar structure, the amyloid fibril precursor 
proteins in AL and ATTR are very diverse and may confer the fibrils differing 
biophysical properties. Recent imaging findings from T1 mapping support this 
hypothesis. T1 mapping is emerging as a tool that allows a more 
comprehensive understanding of the myocyte response and the additional 
mechanisms of myocardial damage in AL amyloidosis, with the potential to 
become an important step in disease characterization.  
CMR has great potential to reshape assessment of patients with 
cardiac amyloidosis through LGE and T1 mapping. These biomarkers are key 
to understanding the pathophysiology of cardiac amyloidosis and to 
characterizing the evidently differing effects of ATTR and AL amyloid 
deposition.  The next challenge will be to implement the transition of these 
biomarkers into more standardized methodologies and then assess their 
robustness in the wider clinical environment.   
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